Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of ACH with genetic confirmation~2. Age between 2 to 10 years old (inclusive) at Screening Visit~3. Prepubertal (Stage 1 breasts for girls or testicular volume \< 4ml for boys) at Screening Visit~4. Able to stand without assistance~5. Caregiver willing and able to administer subcutaneous injections of study drug~Exclusion Criteria:~1. Clinically significant findings at Screening that:~   * are expected to require surgical intervention during participation in the trial or~  * are musculoskeletal in nature, such as Salter-Harris fractures and severe hip pain or~  * otherwise are considered by investigator or Medical Monitor/Medical Expert to make a participant unfit to receive study drug or undergo trial related procedures~2. Have received treatment (\>3 months) of human growth hormone (hGH) or other medications known to affect stature or body proportionality at any time~3. Have received any dose of medications intended to affect stature or body proportionality within the previous 6 months of Screening Visit~4. Have received any study drug or device intended to affect stature or body proportionality at any time~5. History or presence of injury or disease of the growth plate(s), other than Achondroplasia, that affects growth potential of long bones

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- TransCon CNP 6 mcg (Type: EXPERIMENTAL): TransCon CNP 6 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 20 mcg (Type: EXPERIMENTAL): TransCon CNP 20 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 50 mcg (Type: EXPERIMENTAL): TransCon CNP 50 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 100 mcg (Type: EXPERIMENTAL): TransCon CNP 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo mimicking 6, 20, 50, or 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
- Open-Label Extension Period (Type: EXPERIMENTAL): Subjects who complete the 52-week blinded treatment period can continue into the 104-week open-label extension period and will receive treatment with TransCon CNP.

Based on this trial design, predict the completion outcome and termination type (if applicable).